RÉSUMÉ
BACKGROUND: Diabetes mellitus (DM) and coronary microvascular dysfunction (CMD) increase the risk of adverse cardiac events in patients with non-ST-segment elevation myocardial infarction (NSTEMI). This study aimed to evaluate the combined risk estimates of DM and CMD, assessed by the angiography-derived index of microcirculatory resistance (angio-IMR), in patients with NSTEMI. METHODS: A total of 2212 patients with NSTEMI who underwent successful percutaneous coronary intervention (PCI) were retrospectively enrolled from three centers. The primary outcome was a composite of cardiac death or readmission for heart failure at a 2-year follow-up. RESULTS: Post-PCI angio-IMR did not significantly differ between the DM group and the non-DM group (20.13 [17.91-22.70] vs. 20.19 [18.14-22.77], P = 0.530). DM patients exhibited a notably higher risk of cardiac death or readmission for heart failure at 2 years compared to non-DM patients (9.5% vs. 5.4%, P < 0.001). NSTEMI patients with both DM and CMD experienced the highest cumulative incidence of cardiac death or readmission for heart failure at 2 years (24.0%, P < 0.001). The combination of DM and CMD in NSTEMI patients were identified as the most powerful independent predictor for cardiac death or readmission for heart failure at 2 years (adjusted HR: 7.894, [95% CI, 4.251-14.659], p < 0.001). CONCLUSIONS: In patients with NSTEMI, the combination of DM and CMD is an independent predictor of cardiac death or readmission for heart failure. Angio-IMR could be used as an additional evaluation tool for the management of NSTEMI patients with DM. TRIAL REGISTRATION: URL: https://www. CLINICALTRIALS: gov ; Unique identifier: NCT05696379.
Sujet(s)
Coronarographie , Circulation coronarienne , Diabète , Microcirculation , Infarctus du myocarde sans sus-décalage du segment ST , Réadmission du patient , Intervention coronarienne percutanée , Valeur prédictive des tests , Résistance vasculaire , Humains , Mâle , Femelle , Adulte d'âge moyen , Infarctus du myocarde sans sus-décalage du segment ST/imagerie diagnostique , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/physiopathologie , Sujet âgé , Appréciation des risques , Études rétrospectives , Intervention coronarienne percutanée/effets indésirables , Facteurs de risque , Facteurs temps , Diabète/épidémiologie , Diabète/diagnostic , Résultat thérapeutique , Défaillance cardiaque/physiopathologie , Défaillance cardiaque/mortalité , Défaillance cardiaque/diagnostic , Défaillance cardiaque/imagerie diagnostique , Défaillance cardiaque/thérapie , Défaillance cardiaque/épidémiologie , Chine/épidémiologieRÉSUMÉ
BACKGROUND: Complete revascularization improves cardiovascular outcomes compared with culprit-only revascularization in patients with acute myocardial infarction ([MI]; ST-segment-elevation MI or non-ST-segment-elevation MI) and multivessel coronary artery disease. However, the timing of complete revascularization (single-setting versus staged revascularization) is uncertain. The aim was to compare the outcomes of single-setting complete, staged complete, and culprit vessel-only revascularization in patients with acute MI and multivessel disease. METHODS: PubMed, EMBASE, and clinicaltrials.gov databases were searched for randomized controlled trials that compared 3 revascularization strategies. RESULTS: From 16 randomized controlled trials that randomized 11 876 patients with acute MI and multivessel disease, both single-setting complete and staged complete revascularization reduced primary outcome (cardiovascular mortality/MI; odds ratio [OR], 0.52 [95% CI, 0.41-0.65]; OR, 0.74 [95% CI, 0.62-0.88]), composite of all-cause mortality/MI (OR, 0.52 [95% CI, 0.40-0.67]; OR, 0.78 [95% CI, 0.67-0.91]), major adverse cardiovascular event (OR, 0.42 [95% CI, 0.32-0.56]; OR, 0.62 [95% CI, 0.47-0.82]), MI (OR, 0.39 [95% CI, 0.26-0.57]; OR, 0.73 [95% CI, 0.59-0.90]), and repeat revascularization (OR, 0.30 [95% CI, 0.18-0.47]; OR, 0.46 [95% CI, 0.30-0.71]) compared with culprit-only revascularization. Single-setting complete revascularization reduced cardiovascular mortality/MI (OR, 0.70 [95% CI, 0.55-0.91]), major adverse cardiovascular event (OR, 0.67 [95% CI, 0.50-0.91]), and all-cause mortality/MI driven by a lower risk of MI (OR, 0.53 [95% CI, 0.36-0.77]) compared with staged complete revascularization. Single-setting complete revascularization ranked number 1, followed by staged complete revascularization (number 2) and culprit-only revascularization (number 3) for all outcomes. The results were largely consistent in subgroup analysis comparing ST-segment-elevation MI versus non-ST-segment-elevation MI cohorts. CONCLUSIONS: Single-setting complete revascularization may offer the greatest reductions in cardiovascular events in patients with acute MI and multivessel disease. A large-scale randomized trial of single-setting complete versus staged complete revascularization is warranted to evaluate the optimal timing of complete revascularization.
Sujet(s)
Essais contrôlés randomisés comme sujet , Infarctus du myocarde avec sus-décalage du segment ST , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Maladie des artères coronaires/imagerie diagnostique , Maladie des artères coronaires/mortalité , Maladie des artères coronaires/chirurgie , Infarctus du myocarde/mortalité , Revascularisation myocardique/mortalité , Revascularisation myocardique/effets indésirables , Infarctus du myocarde sans sus-décalage du segment ST/imagerie diagnostique , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/chirurgie , Odds ratio , Intervention coronarienne percutanée/effets indésirables , Intervention coronarienne percutanée/mortalité , Récidive , Facteurs de risque , Infarctus du myocarde avec sus-décalage du segment ST/imagerie diagnostique , Infarctus du myocarde avec sus-décalage du segment ST/mortalité , Infarctus du myocarde avec sus-décalage du segment ST/chirurgie , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Despite a significant rise in cardiovascular disease (CVD)-related mortality in low- and middle-income countries (LMICs), data are scarce regarding the quality of care provided, particularly for women. METHODS: This is a prospective observational, cross-sectional study. Acute coronary syndrome (ACS) patients presented to the Cardiology Department at Tanta University, Egypt, between September 1, 2023, and December 31, 2023, were enrolled. The study assessed gender disparities by comparing men and women regarding presentation, management, and major adverse cardiovascular events (MACE) occurrence during hospitalization and 30 days after discharge. RESULTS: A total of 400 ACS patients were included, with 29.5% being women. Women were comparatively older (59 ± 9 years vs. 55 ± 13 years), with a significantly higher prevalence of hypertension (70.3% vs. 47.5%) and diabetes (55% vs. 36.8%). Non-ST-segment elevation myocardial infarction (Non-STEMI) was more common in women (35.29% vs. 21%). Dyspnea was expressed by 34.4% of women (vs. 21.35% of men). Women were hospitalized later (9.29 h vs. 6.74 h). In-hospital outcomes were poorer for women with worse NYHA classes III and IV. Additionally, the odds ratio (OR) for in-hospital cardiac mortality was 0.303 (95% CI 0.103-0.893) for women compared to men. However, a one-month follow-up for MACE post-hospital discharge did not indicate significant gender differences. CONCLUSIONS: The current study suggests that women with ACS in Egypt exhibit a higher risk profile for CVD compared to men and tend to present later with atypical symptoms. Women additionally experience poorer in-hospital MACE and higher cardiac mortality. Therefore, increasing awareness about ACS syndrome and eliminating obstacles that delay hospital admission are imperative.
Sujet(s)
Syndrome coronarien aigu , Disparités de l'état de santé , Disparités d'accès aux soins , Enregistrements , Humains , Femelle , Mâle , Syndrome coronarien aigu/mortalité , Syndrome coronarien aigu/thérapie , Syndrome coronarien aigu/diagnostic , Syndrome coronarien aigu/épidémiologie , Adulte d'âge moyen , Égypte/épidémiologie , Études transversales , Sujet âgé , Facteurs sexuels , Études prospectives , Facteurs temps , Résultat thérapeutique , Adulte , Prévalence , Facteurs de risque , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/diagnostic , Infarctus du myocarde sans sus-décalage du segment ST/épidémiologie , Appréciation des risquesRÉSUMÉ
BACKGROUND: Intensive cardiac care units (ICCUs) were created to manage ventricular arrhythmias after acute coronary syndromes, but have diversified to include a more heterogeneous population, the characteristics of which are not well depicted by conventional methods. AIMS: To identify ICCU patient subgroups by phenotypic unsupervised clustering integrating clinical, biological, and echocardiographic data to reveal pathophysiological differences. METHODS: During 7-22 April 2021, we recruited all consecutive patients admitted to ICCUs in 39 centers. The primary outcome was in-hospital major adverse events (MAEs; death, resuscitated cardiac arrest or cardiogenic shock). A cluster analysis was performed using a Kamila algorithm. RESULTS: Of 1499 patients admitted to the ICCU (69.6% male, mean age 63.3±14.9 years), 67 (4.5%) experienced MAEs. Four phenogroups were identified: PG1 (n=535), typically patients with non-ST-segment elevation myocardial infarction; PG2 (n=444), younger smokers with ST-segment elevation myocardial infarction; PG3 (n=273), elderly patients with heart failure with preserved ejection fraction and conduction disturbances; PG4 (n=247), patients with acute heart failure with reduced ejection fraction. Compared to PG1, multivariable analysis revealed a higher risk of MAEs in PG2 (odds ratio [OR] 3.13, 95% confidence interval [CI] 1.16-10.0) and PG3 (OR 3.16, 95% CI 1.02-10.8), with the highest risk in PG4 (OR 20.5, 95% CI 8.7-60.8) (all P<0.05). CONCLUSIONS: Cluster analysis of clinical, biological, and echocardiographic variables identified four phenogroups of patients admitted to the ICCU that were associated with distinct prognostic profiles. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05063097.
Sujet(s)
Unités de soins intensifs cardiaques , Phénotype , Humains , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Facteurs de risque , Analyse de regroupements , Appréciation des risques , Mortalité hospitalière , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/physiopathologie , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/imagerie diagnostique , Infarctus du myocarde sans sus-décalage du segment ST/diagnostic , Pronostic , Facteurs temps , Choc cardiogénique/physiopathologie , Choc cardiogénique/thérapie , Choc cardiogénique/mortalité , Choc cardiogénique/diagnostic , Études prospectives , Arrêt cardiaque/thérapie , Arrêt cardiaque/physiopathologie , Arrêt cardiaque/diagnostic , Arrêt cardiaque/mortalité , Infarctus du myocarde avec sus-décalage du segment ST/thérapie , Infarctus du myocarde avec sus-décalage du segment ST/physiopathologie , Infarctus du myocarde avec sus-décalage du segment ST/diagnostic , Infarctus du myocarde avec sus-décalage du segment ST/mortalité , Sujet âgé de 80 ans ou plus , Défaillance cardiaque/physiopathologie , Défaillance cardiaque/thérapie , Défaillance cardiaque/diagnostic , Défaillance cardiaque/mortalitéSujet(s)
Marqueurs biologiques , Infarctus du myocarde sans sus-décalage du segment ST , Humains , Marqueurs biologiques/sang , Appréciation des risques/méthodes , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/sang , Infarctus du myocarde sans sus-décalage du segment ST/diagnostic , Facteurs de risque , Pronostic , Valeur prédictive des testsSujet(s)
Infarctus du myocarde , Enregistrements , Humains , Hongrie/épidémiologie , Infarctus du myocarde/thérapie , Infarctus du myocarde/mortalité , Infarctus du myocarde/épidémiologie , Infarctus du myocarde avec sus-décalage du segment ST/thérapie , Infarctus du myocarde avec sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/épidémiologie , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/diagnostic , Femelle , MâleRÉSUMÉ
BACKGROUND: Data on the incidence of type 2 non-ST-segment-elevation myocardial infarction (T2MI) in hospitalized patients with COVID-19 has been limited to single-center studies. Given that certain characteristics, such as obesity and type 2 diabetes, have been associated with higher mortality in COVID-19 infections, we aimed to define the incidence of T2MI in a national cohort and identify pre-hospital patient characteristics associated with T2MI in hospitalized patients with COVID-19. METHODS AND RESULTS: Using the national American Heart Association COVID-19 Cardiovascular Disease Quality Improvement Registry, we performed a retrospective 4:1 matched (age, sex, race, and body mass index) analysis of controls versus cases with T2MI. We performed (1) conditional multivariable logistic regression to identify predictive pre-hospital patient characteristics of T2MI for patients hospitalized with COVID-19 and (2) stratified proportional hazards regression to investigate the association of T2MI with morbidity and mortality. From January 2020 through May 2021, there were 709 (2.2%) out of 32 015 patients with T2MI. Five hundred seventy-nine cases with T2MI were matched to 2171 controls (mean age 70; 43% female). Known coronary artery disease, heart failure, chronic kidney disease, hypertension, payor source, and presenting heart rate were associated with higher odds of T2MI. Anti-hyperglycemic medication and anti-coagulation use before admission were associated with lower odds of T2MI. Those with T2MI had higher morbidity and mortality (hazard ratio, 1.40 [95% CI, 1.13-1.74]; P=0.002). CONCLUSIONS: In hospitalized patients with COVID-19, those with a T2MI compared with those without had higher morbidity and mortality. Outpatient anti-hyperglycemic and anti-coagulation use were the only pre-admission factors associated with reduced odds of T2MI.
Sujet(s)
COVID-19 , Hospitalisation , Infarctus du myocarde sans sus-décalage du segment ST , SARS-CoV-2 , Humains , COVID-19/épidémiologie , COVID-19/mortalité , COVID-19/complications , COVID-19/thérapie , COVID-19/diagnostic , Femelle , Mâle , Sujet âgé , Infarctus du myocarde sans sus-décalage du segment ST/épidémiologie , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/diagnostic , Études rétrospectives , Prévalence , Hospitalisation/statistiques et données numériques , États-Unis/épidémiologie , Facteurs de risque , Adulte d'âge moyen , Enregistrements , Incidence , Mortalité hospitalière , Sujet âgé de 80 ans ou plus , ComorbiditéRÉSUMÉ
BACKGROUND: A short dual antiplatelet therapy (DAPT) duration has been proposed for patients at high bleeding risk (HBR) undergoing drug-eluting coronary stent (DES) implantation. Whether this strategy is safe and effective after a non-ST-segment elevation acute coronary syndrome (NSTE-ACS) remains uncertain. AIMS: We aimed to compare the impact of 1-month versus 3-month DAPT on clinical outcomes after DES implantation among HBR patients with or without NSTE-ACS. METHODS: This is a prespecified analysis from the XIENCE Short DAPT programme involving three prospective, international, single-arm studies evaluating the safety and efficacy of 1-month (XIENCE 28 USA and Global) or 3-month (XIENCE 90) DAPT among HBR patients after implantation of a cobalt-chromium everolimus-eluting stent. Ischaemic and bleeding outcomes associated with 1- versus 3-month DAPT were assessed according to clinical presentation using propensity score stratification. RESULTS: Of 3,364 HBR patients (1,392 on 1-month DAPT and 1,972 on 3-month DAPT), 1,164 (34.6%) underwent DES implantation for NSTE-ACS. At 12 months, the risk of the primary endpoint of death or myocardial infarction was similar between 1- and 3-month DAPT in patients with (hazard ratio [HR] 1.09, 95% confidence interval [CI]: 0.71-1.65) and without NSTE-ACS (HR 0.88, 95% CI: 0.63-1.23; p-interaction=0.34). The key secondary endpoint of Bleeding Academic Research Consortium (BARC) Type 2-5 bleeding was consistently reduced in both NSTE-ACS (HR 0.57, 95% CI: 0.37-0.88) and stable patients (HR 0.84, 95% CI: 0.61-1.15; p-interaction=0.15) with 1-month DAPT. CONCLUSIONS: Among HBR patients undergoing implantation of an everolimus-eluting stent, 1-month, compared to 3-month DAPT, was associated with similar ischaemic risk and reduced bleeding at 1 year, irrespective of clinical presentation.
Sujet(s)
Syndrome coronarien aigu , Endoprothèses à élution de substances , Bithérapie antiplaquettaire , Hémorragie , Intervention coronarienne percutanée , Antiagrégants plaquettaires , Humains , Intervention coronarienne percutanée/effets indésirables , Intervention coronarienne percutanée/méthodes , Intervention coronarienne percutanée/instrumentation , Syndrome coronarien aigu/thérapie , Antiagrégants plaquettaires/usage thérapeutique , Antiagrégants plaquettaires/effets indésirables , Antiagrégants plaquettaires/administration et posologie , Mâle , Adulte d'âge moyen , Sujet âgé , Femelle , Hémorragie/induit chimiquement , Résultat thérapeutique , Bithérapie antiplaquettaire/méthodes , Études prospectives , Facteurs temps , Facteurs de risque , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/mortalitéRÉSUMÉ
BACKGROUND AND AIMS: A routine invasive strategy is recommended in the management of higher risk patients with non-ST-elevation acute coronary syndromes (NSTE-ACSs). However, patients with previous coronary artery bypass graft (CABG) surgery were excluded from key trials that informed these guidelines. Thus, the benefit of a routine invasive strategy is less certain in this specific subgroup. METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. A comprehensive search was performed of PubMed, EMBASE, Cochrane, and ClinicalTrials.gov. Eligible studies were RCTs of routine invasive vs. a conservative or selective invasive strategy in patients presenting with NSTE-ACS that included patients with previous CABG. Summary data were collected from the authors of each trial if not previously published. Outcomes assessed were all-cause mortality, cardiac mortality, myocardial infarction, and cardiac-related hospitalization. Using a random-effects model, risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. RESULTS: Summary data were obtained from 11 RCTs, including previously unpublished subgroup outcomes of nine trials, comprising 897 patients with previous CABG (477 routine invasive, 420 conservative/selective invasive) followed up for a weighted mean of 2.0 (range 0.5-10) years. A routine invasive strategy did not reduce all-cause mortality (RR 1.12, 95% CI 0.97-1.29), cardiac mortality (RR 1.05, 95% CI 0.70-1.58), myocardial infarction (RR 0.90, 95% CI 0.65-1.23), or cardiac-related hospitalization (RR 1.05, 95% CI 0.78-1.40). CONCLUSIONS: This is the first meta-analysis assessing the effect of a routine invasive strategy in patients with prior CABG who present with NSTE-ACS. The results confirm the under-representation of this patient group in RCTs of invasive management in NSTE-ACS and suggest that there is no benefit to a routine invasive strategy compared to a conservative approach with regard to major adverse cardiac events. These findings should be validated in an adequately powered RCT.
Sujet(s)
Syndrome coronarien aigu , Traitement conservateur , Pontage aortocoronarien , Essais contrôlés randomisés comme sujet , Humains , Syndrome coronarien aigu/thérapie , Syndrome coronarien aigu/chirurgie , Traitement conservateur/méthodes , Infarctus du myocarde sans sus-décalage du segment ST/chirurgie , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Intervention coronarienne percutanée/méthodesRÉSUMÉ
Non-ST-segment elevation myocardial infarction (NSTEMI) is a leading cause of emergency hospitalization across Europe. This study evaluates the in-hospital and mid-term outcomes of patients who underwent coronary artery bypass graft (CABG) after NSTEMI. A retrospective analysis of all cases who underwent isolated CABG after NSTEMI from September 2017 to September 2022 at our center. Patients were stratified according to in-hospital survival. Patient characteristics, operative details, and procedural complications were compared between those who survived and those who did not. Predictors of in-hospital and mid-term mortality were evaluated using logistic and Cox regression modeling. Kaplan-Meier analysis was used to generate a survival curve for all alive patients at the time of discharge. Among 1,011 patients (median age 64 [56 to 72] years, 852 [84.3%] male), 735 (72.7%) underwent urgent, 239 (23.6%) elective, and 37 (3.7%) emergency CABG. The in-hospital mortality was 1.5% (15/1,011 patients). Those who died were more likely to be New York Heart Association class III/IV, have left ventricular ejection fraction <21%, severe renal impairment, peripheral vascular disease (PVD), or poor mobility. Emergency procedures, preoperative ventilation, inotropic support, and intra-aortic balloon pump (IABP) use were also more prevalent among those who died. Logistic regression modeling revealed new postoperative stroke (odds ratio 22.0, 95% confidence interval 3.6 to 135.5, p = 0.001), preoperative IABP use (11.4; 2.4 to 53.7, p = 0.002), new hemodialysis (9.6; 2.7 to 34.7, p <0.001), PVD (5.6; 1.6 to 20.0, p = 0.008), and poor mobility (odds ratio 4.8, 95% confidence interval 1.3 to 18.2, p = 0.022) as independent predictors of in-hospital mortality. In conclusion, new postoperative stroke, preoperative IABP use, new hemodialysis, PVD, and poor mobility are independent predictors of mortality in patients with NSTEMI who underwent isolated CABG.
Sujet(s)
Pontage aortocoronarien , Mortalité hospitalière , Infarctus du myocarde sans sus-décalage du segment ST , Humains , Mâle , Femelle , Sujet âgé , Mortalité hospitalière/tendances , Adulte d'âge moyen , Études rétrospectives , Infarctus du myocarde sans sus-décalage du segment ST/chirurgie , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Complications postopératoires/épidémiologie , Taux de survie/tendances , Facteurs de risqueRÉSUMÉ
BACKGROUND: Individuals with both atrial fibrillation (AF) and myocardial infarction (MI) have higher mortality compared with individuals with only 1 condition. Whether mortality differs according to the temporal order of AF and MI is unclear. METHODS AND RESULTS: We included participants from the FHS (Framingham Heart Study) from 1960 and onwards. We assessed the hazard ratio (HR) of new-onset AF and MI, and mortality according to MI and AF status (prevalent and interim) using multivariable-adjusted Cox proportional hazards models. Interim diseases were modeled as time-varying variables. For the analysis of new-onset AF, 10 923 participants (55% women; mean±SD age, 54±8 years) were included. For new-onset MI, 10 804 participants (55% women; mean±SD age, 54±8 years) were included. Compared with no MI, the hazard of new-onset AF was higher in participants with prevalent (HR, 1.60 [95% CI, 1.32-1.94]) and interim MI (HR, 3.96 [95% CI, 3.18-4.91]). Both ST-segment-elevation MI and non-ST-segment-elevation MI were associated with new-onset AF. Interim AF, not prevalent AF, was associated with higher hazard rate of new-onset MI (HR, 2.21 [95% CI, 1.67-2.92]). Interim AF was associated with both ST-segment-elevation MI and non-ST-segment-elevation MI. Mortality was significantly greater among participants with AF and MI compared with participants with 1 of the 2, regardless of temporal order. CONCLUSIONS: We report a bidirectional association between AF and MI, which was observed for both non-ST-segment-elevation MI and ST-segment-elevation MI. Participants with both AF and MI had considerably higher mortality compared with participants with only 1 of the 2 conditions, regardless of order.
Sujet(s)
Fibrillation auriculaire , Humains , Fibrillation auriculaire/mortalité , Fibrillation auriculaire/épidémiologie , Fibrillation auriculaire/complications , Femelle , Adulte d'âge moyen , Mâle , Sujet âgé , Facteurs de risque , Facteurs temps , Prévalence , Infarctus du myocarde avec sus-décalage du segment ST/mortalité , Infarctus du myocarde avec sus-décalage du segment ST/épidémiologie , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/diagnostic , Infarctus du myocarde sans sus-décalage du segment ST/épidémiologie , Appréciation des risques/méthodes , Infarctus du myocarde/mortalité , Infarctus du myocarde/épidémiologie , Massachusetts/épidémiologie , Modèles des risques proportionnels , PronosticRÉSUMÉ
BACKGROUND: Cardiovascular disease is the major cause of morbidity and mortality, particularly in type 2 diabetes mellitus (T2DM). Novel markers of insulin resistance and progression of atherosclerosis include the triglycerides and glucose index (TyG index), the triglycerides and body mass index (Tyg-BMI) and the metabolic score for insulin resistance (METS-IR). Establishing independent risk factors for in-hospital death and major adverse cardiac and cerebrovascular events (MACCE) in patients with myocardial infarction (MI) remains critical. The aim of the study was to assess the risk of in-hospital death and MACCE within 12 months after ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) in patients with and without T2DM based on TyG index, Tyg-BMI and METS-IR. METHODS: Retrospective analysis included 1706 patients with STEMI and NSTEMI hospitalized between 2013 and 2021. We analyzed prognostic value of TyG index, Tyg-BMI and METS-IR for in-hospital death and MACCE as its components (death from any cause, MI, stroke, revascularization) within 12 months after STEMI or NSTEMI in patients with and without T2DM. RESULTS: Of 1706 patients, 58 in-hospital deaths were reported (29 patients [4.3%] in the group with T2DM and 29 patients [2.8%] in the group without T2DM; p = 0.1). MACCE occurred in 18.9% of the total study population (25.8% in the group with T2DM and 14.4% in the group without T2DM; p < 0.001). TyG index, Tyg-BMI and METS-IR were significantly higher in the group of patients with T2DM compared to those without T2DM (p < 0.001). Long-term MACCE were more prevalent in patients with T2DM (p < 0.001). The area under the ROC curve (AUC-ROC) for the prediction of in-hospital death and the TyG index was 0.69 (p < 0.001). The ROC curve for predicting in-hospital death based on METS-IR was 0.682 (p < 0.001). The AUC-ROC values for MACCE prediction based on the TyG index and METS-IR were 0.582 (p < 0.001) and 0.57 (p < 0.001), respectively. CONCLUSIONS: TyG index was an independent risk factor for in-hospital death in patients with STEMI or NSTEMI. TyG index, TyG-BMI and METS-IR were not independent risk factors for MACCE at 12 month follow-up. TyG index and METS-IR have low predictive value in predicting MACCE within 12 months after STEMI and NSTEMI.
Sujet(s)
Marqueurs biologiques , Glycémie , Diabète de type 2 , Mortalité hospitalière , Insulinorésistance , Infarctus du myocarde sans sus-décalage du segment ST , Infarctus du myocarde avec sus-décalage du segment ST , Humains , Diabète de type 2/sang , Diabète de type 2/diagnostic , Diabète de type 2/mortalité , Diabète de type 2/complications , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Appréciation des risques , Pronostic , Marqueurs biologiques/sang , Études rétrospectives , Facteurs temps , Infarctus du myocarde sans sus-décalage du segment ST/sang , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/diagnostic , Glycémie/métabolisme , Infarctus du myocarde avec sus-décalage du segment ST/sang , Infarctus du myocarde avec sus-décalage du segment ST/mortalité , Infarctus du myocarde avec sus-décalage du segment ST/diagnostic , Infarctus du myocarde avec sus-décalage du segment ST/thérapie , Facteurs de risque , Indice de masse corporelle , Valeur prédictive des tests , Triglycéride/sang , Sujet âgé de 80 ans ou plusRÉSUMÉ
BACKGROUND: Patients with prior coronary artery bypass grafting (CABG) presenting with an acute coronary syndrome (ACS) have poor outcomes and the optimal treatment strategy for this population is unknown. METHODS: Using linked administrative databases, we examined patients with an ACS between 2008 and 2019, identifying patients with prior CABG. Patients were categorized by ACS presentation type and treatment strategy. Our primary outcome was the composite of death and recurrent myocardial infarction at one year. RESULTS: Of 54,641 patients who presented with an ACS, 1670 (3.1%) had a history of prior CABG. Of those, 11.0% presented with an ST-elevation myocardial infarction (STEMI) of which, 15.3% were treated medically, 31.1% underwent angiography but were treated medically, 22.4% with fibrinolytic therapy and 31.1% with primary PCI. The primary outcome rate was the highest (36.8%) in patients who did not undergo angiography and was similar in the primary PCI (20.8%) and fibrinolytic group (21.9%). In patients presenting with a non-ST elevation acute coronary syndrome (NSTE-ACS) (89.0%), 33.2% were treated medically, 38.5% underwent angiography but were treated medically and 28.2% were treated with PCI. Compared to those who underwent PCI, patients treated conservatively demonstrated a higher risk of the composite outcome (14.8% vs 27.3%; adjusted hazard ratio 1.70, 95% confidence interval 1.22-2.37). CONCLUSIONS: Patients with prior CABG presenting with an ACS are often treated conservatively without PCI, which is associated with a higher risk of adverse events.
Sujet(s)
Syndrome coronarien aigu , Coronarographie , Pontage aortocoronarien , Intervention coronarienne percutanée , Humains , Syndrome coronarien aigu/thérapie , Syndrome coronarien aigu/diagnostic , Syndrome coronarien aigu/mortalité , Syndrome coronarien aigu/imagerie diagnostique , Pontage aortocoronarien/effets indésirables , Mâle , Femelle , Sujet âgé , Adulte d'âge moyen , Résultat thérapeutique , Intervention coronarienne percutanée/effets indésirables , Récidive , Facteurs de risque , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/chirurgie , Infarctus du myocarde sans sus-décalage du segment ST/imagerie diagnostique , Infarctus du myocarde sans sus-décalage du segment ST/diagnostic , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Facteurs temps , Infarctus du myocarde avec sus-décalage du segment ST/thérapie , Infarctus du myocarde avec sus-décalage du segment ST/diagnostic , Infarctus du myocarde avec sus-décalage du segment ST/chirurgie , Infarctus du myocarde avec sus-décalage du segment ST/imagerie diagnostique , Études rétrospectives , Bases de données factuelles , Traitement thrombolytique/effets indésirables , Appréciation des risquesRÉSUMÉ
BACKGROUND AND AIMS: Older patients with non-ST-elevation acute coronary syndrome (NSTEACS) are less likely to receive guideline-recommended care including coronary angiography and revascularization. Evidence-based recommendations regarding interventional management strategies in this patient cohort are scarce. This meta-analysis aimed to assess the impact of routine invasive vs. conservative management of NSTEACS by using individual patient data (IPD) from all available randomized controlled trials (RCTs) including older patients. METHODS: MEDLINE, Web of Science and Scopus were searched between 1 January 2010 and 11 September 2023. RCTs investigating routine invasive and conservative strategies in persons >70 years old with NSTEACS were included. Observational studies or trials involving populations outside the target range were excluded. The primary endpoint was a composite of all-cause mortality and myocardial infarction (MI) at 1 year. One-stage IPD meta-analyses were adopted by use of random-effects and fixed-effect Cox models. This meta-analysis is registered with PROSPERO (CRD42023379819). RESULTS: Six eligible studies were identified including 1479 participants. The primary endpoint occurred in 181 of 736 (24.5%) participants in the invasive management group compared with 215 of 743 (28.9%) participants in the conservative management group with a hazard ratio (HR) from random-effects model of 0.87 (95% CI 0.63-1.22; P = .43). The hazard for MI at 1 year was significantly lower in the invasive group compared with the conservative group (HR from random-effects model 0.62, 95% CI 0.44-0.87; P = .006). Similar results were seen for urgent revascularization (HR from random-effects model 0.41, 95% CI 0.18-0.95; P = .037). There was no significant difference in mortality. CONCLUSIONS: No evidence was found that routine invasive treatment for NSTEACS in older patients reduces the risk of a composite of all-cause mortality and MI within 1 year compared with conservative management. However, there is convincing evidence that invasive treatment significantly lowers the risk of repeat MI or urgent revascularisation. Further evidence is needed from ongoing larger clinical trials.
Sujet(s)
Syndrome coronarien aigu , Traitement conservateur , Intervention coronarienne percutanée , Humains , Traitement conservateur/méthodes , Syndrome coronarien aigu/thérapie , Syndrome coronarien aigu/mortalité , Sujet âgé , Essais contrôlés randomisés comme sujet , Revascularisation myocardique/statistiques et données numériques , Coronarographie , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , FemelleRÉSUMÉ
BACKGROUND: Older people are underrepresented in randomized trials. The association between lipid-lowering therapy (LLT) and its intensity after acute myocardial infarction and long-term mortality in this population deserves to be assessed. METHODS: The FAST-MI (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) program consists of nationwide French surveys including all patients admitted for acute myocardial infarction ≤48 hours from onset over a 1- to 2-month period in 2005, 2010, and 2015, with long-term follow-up. Numerous data were collected and a centralized 10-year follow-up was organized. The present analysis focused on the association between prescription of LLT (atorvastatin ≥40 mg or equivalent, or any combination of statin and ezetimibe) and 5-year mortality in patients aged ≥80 years discharged alive. Cox multivariable analysis and propensity score matching were used to adjust for baseline differences. RESULTS: Among the 2258 patients aged ≥80 years (mean age, 85±4 years; 51% women; 39% ST-segment elevation myocardial infarction; 58% with percutaneous coronary intervention), 415 were discharged without LLT (18%), 866 with conventional doses (38%), and 977 with high-dose LLT (43%). Five-year survival was 36%, 47.5%, and 58%, respectively. Compared with patients without LLT, high-dose LLT was significantly associated with lower 5-year mortality (adjusted hazard ratio, 0.78 [95% CI, 0.66-0.92]), whereas conventional-intensity LLT was not (adjusted hazard ratio, 0.93 [95% CI, 0.80-1.09]). In propensity score-matched cohorts (n=278 receiving high-intensity LLT and n=278 receiving no statins), 5-year survival was 52% with high-intensity LLT at discharge and 42% without statins (hazard ratio, 0.78 [95% CI, 0.62-0.98]). CONCLUSIONS: In these observational cohorts, high-intensity LLT at discharge after acute myocardial infarction was associated with reduced all-cause mortality at 5 years in an older adult population. These results suggest that high-intensity LLT should not be denied to patients on the basis of old age. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT00673036, NCT01237418, and NCT02566200.
Sujet(s)
Ézétimibe , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase , Infarctus du myocarde sans sus-décalage du segment ST , Enregistrements , Infarctus du myocarde avec sus-décalage du segment ST , Humains , Femelle , Mâle , Facteurs temps , France/épidémiologie , Sujet âgé de 80 ans ou plus , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/administration et posologie , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/usage thérapeutique , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/effets indésirables , Résultat thérapeutique , Infarctus du myocarde avec sus-décalage du segment ST/mortalité , Infarctus du myocarde avec sus-décalage du segment ST/thérapie , Infarctus du myocarde avec sus-décalage du segment ST/diagnostic , Facteurs âges , Facteurs de risque , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/diagnostic , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Ézétimibe/usage thérapeutique , Ézétimibe/effets indésirables , Ézétimibe/administration et posologie , Appréciation des risques , Dyslipidémies/traitement médicamenteux , Dyslipidémies/mortalité , Dyslipidémies/diagnostic , Dyslipidémies/sang , Atorvastatine/administration et posologie , Atorvastatine/effets indésirables , Association de médicaments , Intervention coronarienne percutanée/mortalité , Intervention coronarienne percutanée/effets indésirables , Lipides/sangRÉSUMÉ
BACKGROUND: Limited data exist regarding the prognostic implications of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with non-ST-elevation myocardial infarction (NSTEMI) who undergo percutaneous coronary intervention (PCI). METHODSâANDâRESULTS: Of 13,104 patients in the nationwide Korea Acute Myocardial Infarction Registry-National Institutes of Health, 3,083 patients with NSTEMI who underwent PCI were included in the present study. The primary endpoint was major adverse cardiovascular events (MACE) at 3 years, a composite of all-cause death, recurrent myocardial infarction, unplanned repeat revascularization, and admission for heart failure. NT-proBNP was measured at the time of initial presentation for the management of NSTEMI, and patients were divided into a low (<700 pg/mL; n=1,813) and high (≥700 pg/mL; n=1,270) NT-proBNP group. The high NT-proBNP group had a significantly higher risk of MACE, driven primarily by a higher risk of cardiac death or admission for heart failure. These results were consistent after confounder adjustment by propensity score matching and inverse probability weighting analysis. CONCLUSIONS: In patients with NSTEMI who underwent PCI, an initial elevated NT-proBNP concentration was associated with higher risk of MACE at 3 years, driven primarily by higher risks of cardiac death or admission for heart failure. These results suggest that the initial NT-proBNP concentration may have a clinically significant prognostic value in NSTEMI patients undergoing PCI.
Sujet(s)
Peptide natriurétique cérébral , Infarctus du myocarde sans sus-décalage du segment ST , Fragments peptidiques , Intervention coronarienne percutanée , Enregistrements , Humains , Peptide natriurétique cérébral/sang , Fragments peptidiques/sang , Sujet âgé , Mâle , Femelle , Adulte d'âge moyen , Infarctus du myocarde sans sus-décalage du segment ST/sang , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/diagnostic , République de Corée/épidémiologie , Pronostic , Défaillance cardiaque/sang , Défaillance cardiaque/mortalité , Marqueurs biologiques/sangRÉSUMÉ
BACKGROUND: Women with acute myocardial infarction (AMI) often present a worse risk profile and experience a higher rate of in-hospital mortality than men. However, sex differences in post-discharge prognoses remain inadequately investigated. We examined the impact of sex on 1-year post-discharge outcomes in patients with AMI undergoing percutaneous coronary intervention. METHODSâANDâRESULTS: We extracted patient-level data for the period January 2017-December 2018 from the J-PCI OUTCOME Registry, endorsed by the Japanese Association of Cardiovascular Intervention and Therapeutics. One-year all-cause and cardiovascular mortality and major adverse cardiovascular events were compared between men and women. In all, 29,856 AMI patients were studied, with 6,996 (23.4%) being women. Women were significantly older and had a higher prevalence of comorbidities than men. Crude all-cause mortality was significantly higher among women than men (7.5% vs. 5.4% [P<0.001] for ST-elevation myocardial infarction [STEMI]; 7.0% vs. 5.2% [P=0.006] for non-STEMI). These sex-related differences in post-discharge outcomes were attenuated after stratification by age. Multivariate analysis demonstrated an increase in all-cause mortality in both sexes with increasing age and advanced-stage chronic kidney disease (CKD). CONCLUSIONS: Within this nationwide cohort, women had worse clinical outcomes following AMI than men. However, these sex-related differences in outcomes diminished after adjusting for age. In addition, CKD was significantly associated with all-cause mortality in both sexes.
Sujet(s)
Intervention coronarienne percutanée , Enregistrements , Humains , Femelle , Mâle , Sujet âgé , Japon/épidémiologie , Adulte d'âge moyen , Intervention coronarienne percutanée/mortalité , Facteurs sexuels , Mortalité hospitalière , Sujet âgé de 80 ans ou plus , Résultat thérapeutique , Infarctus du myocarde/mortalité , Infarctus du myocarde/chirurgie , Infarctus du myocarde/thérapie , Infarctus du myocarde avec sus-décalage du segment ST/chirurgie , Infarctus du myocarde avec sus-décalage du segment ST/mortalité , Facteurs de risque , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/chirurgie , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Comorbidité , Peuples d'Asie de l'EstRÉSUMÉ
BACKGROUND: Limited data are available on patients with chronic lung disease (CLD) presenting with acute myocardial infarction (AMI). We aimed to analyse baseline characteristics, treatment and outcome of those patients enrolled in the Swiss nationwide prospective AMIS Plus registry. METHODS: All AMI patients enrolled between January 2002 and December 2021 with data on CLD, as defined in the Charlson Comorbidity Index, were included. The primary endpoints were in-hospital mortality and major adverse cardiac and cerebrovascular events (MACCE), defined as all-cause death, reinfarction and cerebrovascular events. Baseline characteristics, in-hospital treatments and outcomes were analysed using descriptive statistics and logistic regression. RESULTS: Among 53,680 AMI patients enrolled during this time, 5.8% had CLD. Compared with patients without CLD, CLD patients presented more frequently with non-ST-elevation myocardial infarction (MI) and type 2 MI (12.8% vs. 6.5%, p < 0.001). With respect to treatment, CLD patients were less likely to receive P2Y12 inhibitors (p < 0.001) and less likely to undergo percutaneous coronary interventions (68.7% vs. 82.5%; p < 0.001). In-hospital mortality declined in AMI patients with CLD over time (from 12% in 2002 to 7.3% in 2021). Multivariable regression analysis showed that CLD was an independent predictor for MACCE (adjusted OR was 1.28 [95% CI 1.07-1.52], p = 0.006). CONCLUSION: Patients with CLD and AMI were less likely to receive evidence-based pharmacologic treatments, coronary revascularization and had a higher incidence of MACCE during their hospital stay compared to those without CLD. Over 20 years, in-hospital mortality was significantly reduced in AMI patients, especially in those with CLD.
Sujet(s)
Mortalité hospitalière , Infarctus du myocarde , Intervention coronarienne percutanée , Enregistrements , Humains , Femelle , Mâle , Sujet âgé , Infarctus du myocarde/épidémiologie , Infarctus du myocarde/thérapie , Adulte d'âge moyen , Intervention coronarienne percutanée/statistiques et données numériques , Maladie chronique , Suisse/épidémiologie , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/épidémiologie , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Antagonistes des récepteurs purinergiques P2Y/usage thérapeutique , Sujet âgé de 80 ans ou plus , Maladies pulmonaires/épidémiologie , Angiopathies intracrâniennes/épidémiologie , Angiopathies intracrâniennes/thérapie , Récidive , Résultat thérapeutique , Cause de décèsRÉSUMÉ
BACKGROUND: As life expectancy increases, the population of older individuals with coronary artery disease and frailty is growing. We aimed to assess the impact of patient-reported frailty on the treatment and prognosis of elderly early survivors of non-ST-elevation acute coronary syndrome (NSTE-ACS). METHODS: Frailty data were obtained from two prospective trials, POPular Age and the POPular Age Registry, which both assessed elderly NSTE-ACS patients. Frailty was assessed one month after admission with the Groningen Frailty Indicator (GFI) and was defined as a GFI-score of 4 or higher. In these early survivors of NSTE-ACS, we assessed differences in treatment and 1-year outcomes between frail and non-frail patients, considering major adverse cardiovascular events (MACE, including cardiovascular mortality, myocardial infarction, and stroke) and major bleeding. RESULTS: The total study population consisted of 2192 NSTE-ACS patients, aged ≥70 years. The GFI-score was available in 1320 patients (79 ± 5 years, 37% women), of whom 712 (54%) were considered frail. Frail patients were at higher risk for MACE than non-frail patients (9.7% vs. 5.1%, adjusted hazard ratio [HR] 1.57, 95% confidence interval [CI] 1.01-2.43, p = 0.04), but not for major bleeding (3.7% vs. 2.8%, adjusted HR 1.23, 95% CI 0.65-2.32, p = 0.53). Cubic spline analysis showed a gradual increase of the risk for clinical outcomes with higher GFI-scores. CONCLUSIONS: In elderly NSTE-ACS patients who survived 1-month follow-up, patient-reported frailty was independently associated with a higher risk for 1-year MACE, but not with major bleeding. These findings emphasize the importance of frailty screening for risk stratification in elderly NSTE-ACS patients.
Sujet(s)
Syndrome coronarien aigu , Personne âgée fragile , Fragilité , Humains , Sujet âgé , Femelle , Mâle , Fragilité/épidémiologie , Fragilité/diagnostic , Syndrome coronarien aigu/épidémiologie , Sujet âgé de 80 ans ou plus , Études prospectives , Personne âgée fragile/statistiques et données numériques , Enregistrements , Mesures des résultats rapportés par les patients , Études de suivi , Résultat thérapeutique , Infarctus du myocarde sans sus-décalage du segment ST/épidémiologie , Infarctus du myocarde sans sus-décalage du segment ST/mortalitéRÉSUMÉ
BACKGROUND: Prior studies have reported decreased use of an invasive approach for acute myocardial infarction (AMI) in patients undergoing transcatheter aortic valve replacement (TAVR). OBJECTIVES: The aim of this study was to determine whether prior TAVR affects the use of subsequent coronary revascularization and outcomes of AMI in a contemporary national data set. METHODS: Consecutive TAVR patients from 2016 to 2022 were identified from the U.S. Vizient Clinical Data Base who were hospitalized after the index TAVR hospitalization with ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI). Patients with STEMI or NSTEMI with or without prior TAVR from the same time period were compared for the use of coronary angiography, revascularization, and in-hospital outcomes. Propensity score matching was used to account for imbalances in patient characteristics. RESULTS: Among 206,229 patients who underwent TAVR, the incidence of STEMI was 25 events per 100,000 person-years of follow-up, and that of NSTEMI was 229 events per 100,000 person-years. After propensity matching, the use of coronary revascularization was similar in the prior TAVR and no TAVR cohorts in both the STEMI (65.3% vs 63.9%; P = 0.81) and NSTEMI (41.4% vs 41.7%; P = 0.88) subgroups. Compared with patients without prior TAVR, in-hospital mortality was higher in the prior TAVR cohort in patients with STEMI (27.1% vs 16.7%; P = 0.03) and lower in those with NSTEMI (5.8% vs 8.2%; P = 0.02). CONCLUSIONS: In this large, national retrospective study, AMI events after TAVR were infrequent. There were no differences in the use of coronary revascularization for STEMI or NSTEMI in TAVR patients compared with the non-TAVR population. In-hospital mortality for STEMI is higher in TAVR patients compared with those without prior TAVR.